Search clinical trials for: NP101

Total 26 results

Neuracle Genetics, Inc
ORA, Inc.

Recruiting

NG101 AAV Gene Therapy in Subjects With Wet Age-Related Macular Degeneration

Age-Related Macular Degeneration

Canada
NuPathe Inc.

Completed

An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over Twelve Months (NP101-009)

Migraine Disorders

United States
NuPathe Inc.

Completed

An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over 12 Months (NP101-008)

Migraine Disorders

United States
Ivix LLX

Completed

Study of the Efficacy and Safety of BP101 in Female Patients With Decrease or Loss of Sexual Desire

Hypoactive Sexual Desire Disorder (HSDD)

Russian Federation
Neuraltus Pharmaceuticals, Inc.

Completed

A Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis

United States
Neuraltus Pharmaceuticals, Inc.

Completed

Single-Ascending-Dose Safety/Tolerability of NP001 in Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis

United States
Finch Research and Development LLC.

Terminated

A Trial of CP101 for the Prevention of Recurrent CDI (PRISM4) (PRISM4)

Recurrent C. Difficile Infection

United States, Canada
Ivix LLX

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BP101 in Healthy Volunteers

Hypoactive Sexual Desire Disorder(HSDD)

Russian Federation
Beau Nakamoto
Neuraltus Pharmaceuticals, Inc.

Terminated

NP001, Alzheimer's Disease, and Blood Markers of Inflammation

Alzheimer Disease

United States
Universidad Complutense de Madrid

Recruiting

Ligilactobacillus Salivarius MP101 for Elderly in a Nursing Home (PROBELDERLY)

Covid19

Spain
Ivix LLX

Completed

BP101 for Adults With Female Sexual Dysfunction

Female Sexual Dysfunction | Hypoactive Sexual Desire Disorder | Sexual Desire Disorder

Russian Federation
Neuraltus Pharmaceuticals, Inc.

Completed

Safety and Efficacy Study of NP001 in Patients With Amyotrophic Lateral Sclerosis (ALS) and Systemic Inflammation

Amyotrophic Lateral Sclerosis

United States, Canada
Finch Research and Development LLC.

Withdrawn

Efficacy, Safety, and Tolerability Study of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Autism Spectrum Disorder and Associated GI Symptoms (SPROUT) (SPROUT)

Autism Spectrum Disorder | Autism | ASD | FMT | Fecal Transplant | Autistic Thinking | Autistic Behavior | Fecal Microbiota Transplant | Finch | CP101 | SPROUT
NuPathe Inc.

Completed

The Efficacy and Tolerability of NP101 Patch in the Treatment of Acute Migraine (NP101-007)

Migraine Disorders

United States
Neuracle Science Co., LTD.
Samsung Medical Center; Korea University Anam Hospital; Severance Hospital

Recruiting

A Phase 1b/2a, Study Evaluating the Safety, PK/PD and Efficacy of NS101 in Healthy Volunteers and SSNHL Patients

Sudden Sensorineural Hearing Loss | Seneorineural Deafness

Korea, Republic of
Neuracle Science Co., LTD.

Completed

A FIH Study to Assess the Safety and Tolerability of NS Intravenous NS101 Infusion

Neurodegenerative Diseases

Canada
Finch Research and Development LLC.

Completed

Efficacy, Safety, and Tolerability Study of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Recurrent C. Diff (PRISM3)

Clostridium Difficile Infection Recurrence

Canada, United States
Finch Research and Development LLC.
Medpace, Inc.

Completed

Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiota™ (CP101) in Subjects With Recurrence of Clostridium Difficile Infection (PRISM-EXT)

Clostridium Difficile Infection | Recurrent Clostridium Difficile Infection | C. Diff | CDI | Recurrent C. Diff | rCDI | C. Difficile | Recurrent CDI | FMT | Fecal Microbiota | Fecal Transplant

United States, Canada
NuPathe Inc.

Completed

Compare PK and Bioavailability of 2 NP101 Patches With Oral Imitrex in Healthy Adults

Compare Bioequivalence Patches Previously Used in the NP101-007 Study

United States
NuPathe Inc.

Completed

Safety, Pharmacokinetic, and Tolerability Study of Zecuity® in Adolescent Subjects With a History of Acute Migraine

Acute Migraine
NuPathe Inc.

Completed

Phase I Open Label Single-Dose Study to Compare the Pharmacokinetics of NP101 Healthy Volunteers (NP101-006)

Migraine Disorders

United States
Neurogastrx, Inc.

Completed

A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants With Symptomatic Diabetic or Idiopathic Gastroparesis

Diabetic Gastroparesis | Idiopathic Gastroparesis

United States
NuPathe Inc.

Completed

Phase I, Open Label, Single-Dose, Four Way Crossover Study to Compare the PK of NP101 With Oral Imitrex® (50mg) in Migraine Subjects During an Acute Migraine Attack and During a Non-Migraine Period (NP101-011)

Migraine Disorders

United States
Redwood Pharma AB
Cross Research S.A.

Completed

Effects of RP101 in Post-menopausal Women With Dry Eye Syndrome

Dry Eye Syndromes

Austria, Germany, Hungary
SciClone Pharmaceuticals

Terminated

Phase II Study to Evaluate Efficacy and Safety of RP101 in Combination With Gemcitabine (RP101)

Pancreatic Cancer

United States, Chile, Spain, Brazil, Argentina, France, Germany, Hungary, Netherlands, Peru, Poland, Romania, United Kingdom
NeuroTau, Inc.
The Cleveland Clinic

Unknown

Evaluation of Tolfenamic Acid in Individuals With PSP at 12-Weeks

Progressive Supranuclear Palsy

United States

Search clinical trials for: NP101

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Kingdom

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations